TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01052116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavone supplement
Description: Oral soy isoflavone supplement (100 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02288832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -self-collected vaginal samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zithromax

Intervention type: OTHER
Group type: OTHER
Intervention: usual practices
Study: NCT04665947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Description: PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
Study: NCT00365300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01964742

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood samples
Study: NCT02715869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A pharmacologic cardiac preconditioning (Sevoflurane)
Description: A Patients are anaesthetized by Sevoflurane more than 1 mac.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B ischeamic preconditioning
Description: B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
Study: NCT02325271

Intervention type: OTHER
Intervention: Frequent blood and urine sampling and blood pressure measurement
Description: Blood and urine sampling for the determination of VEGF and biomarkers

Intervention type: OTHER
Intervention: Frequent blood and urine sampling and blood pressure measurement
Description: Blood and urine sampling for the determination of VEGF and biomarkers
Study: NCT00605748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental PV-Isolation of the arrhythmogenic vein(s)
Description: isolation of pulmonary veins for curing atrial fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental PV-Isolation of all veins
Description: isolation of pulmonary veins for curing atrial fibrillation
Study: NCT01168505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric hydroxide saccharate
Description: single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
Study: NCT03886090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rest
Description: Seated rest following motor skill practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor learning
Description: Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
Study: NCT01411332

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIMRT
Description: A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HTIMRT
Description: Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
Study: NCT01179490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
Study: NCT03308019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Description: In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
Study: NCT02563197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-326 Inhaler
Description: No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
Study: NCT03724149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study: NCT04912349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TUSP
Description: Patients received the transurethral split of the prostate(TUSP) treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Patients received the transurethral resection of the prostate(TURP) treatment.
Study: NCT03409601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Portion Size
Description: Meal portion size at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125% Portion Size
Description: Meal portion size 125% of baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150% Portion Size
Description: Meal portion size 150% of baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 175% Portion Size
Description: Meal portion size 175% of baseline
Study: NCT01159548

Intervention type: DRUG
Group type: OTHER
Intervention: Promethazine

Intervention type: DRUG
Group type: OTHER
Intervention: Promethazine
Study: NCT03881826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of clinical data and biological samples
Description: * nutritional assessement~* cachexia symptoms~* urine, feces and blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collection of clinical data and biological samples
Description: * nutritional assessement~* cachexia symptoms~* urine, feces and blood samples
Study: NCT03923764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein and energy diet
Description: Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Diet
Description: Patients continue their usual diet
Study: NCT04005664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Prophylactic phenylephrine infusion as part of fluid coload
Study: NCT04277910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MT2004
Description: MT2004 oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules
Study: NCT01783171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01651702

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carto
Description: Group of patients where Carto Express system will be used for electroanatomical mapping.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ensite
Description: Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
Study: NCT02822248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-64-R84-070)
Study: NCT01189669

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LC n-3 PUFA (fish oil) Supplement
Description: 4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (olive oil) supplement
Description: 4 x 1g olive oil capsules were given daily for 6 weeks
Study: NCT04797403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-care protocol adapted from the SPRINT intensive-treatment algorithm
Description: The core component of the intervention is protocol-based treatment using the SPRINT intensive BP management algorithm. Implementation strategies include dissemination of SPRINT study findings, team-based collaborative care and shared-decision making, blood pressure audit and feedback, home blood pressure monitoring, and health coaching.
Study: NCT04426799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lemon essential oil
Description: A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul
Study: NCT01402947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin XR + MMX Placebo
Description: MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalazine/mesalamine + Ciprofloxacin XR
Description: MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
Study: NCT04352361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, matching number of placebo Tablets with active arm.
Study: NCT04475965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise for shoulder external rotators
Description: The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise for shoulder external rotators
Description: The intervention included the application of a series of isometric contraction for the external rotators shoulder muscles. The exercise protocol included two intensities; high-level isometric contraction (80% maximal voluntary isometric contraction) versus a low-level isometric contraction (20% maximal voluntary isometric contraction).
Study: NCT03634709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Flexibility training (MemFlex)
Description: MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
Study: NCT02041871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral immunonutrition
Description: Powder 74g within 250ml of water, 3 times per day during 7 days before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
Study: NCT01185808

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 5000IU/day for 6 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 5000IU/day for 6 weeks
Study: NCT02857270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered IV
Study: NCT02305966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All patients will receive a Delta XTEND reverse shoulder implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All patients will receive a Delta XTEND reverse shoulder implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All patients will receive a Delta XTEND reverse shoulder implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: All patients will receive a Delta XTEND reverse shoulder implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 0.8 mm diameter Tantalum marker beads
Description: At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 0.8 mm diameter Tantalum marker beads
Description: At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 0.8 mm diameter Tantalum marker beads
Description: At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 0.8 mm diameter Tantalum marker beads
Description: At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
Study: NCT02977520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Printing, Three-Dimensional
Description: To establish 3D model of cerebral aneurysms and have preoperative evaluation.
Study: NCT04382937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 + Ribavirin
Description: P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Intron + Ribavirin
Description: PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily
Study: NCT01061125

Intervention type: OTHER
Intervention: TTM and Holter monitor
Description: Standard of care visits recordings reviewed during clinical visits

Intervention type: OTHER
Intervention: TTM and Holter monitor
Description: Standard of care visits recordings reviewed during clinical visits
Study: NCT04125706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Topical
Description: Minocycline will be delivered locally in the periodontal pocket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Topical Gel
Description: Metronidazole will be delivered locally in the periodontal pocket
Study: NCT02246478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-205
Description: * Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-205
Description: * Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-205
Description: * Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals